- Home
- JNJ
JNJ
Johnson & Johnson
as 07-26-2024 4:00pm EST
| Founded: | 1886 | Country: | United States |
| Employees: | N/A | City: | NEW BRUNSWICK |
| Market Cap: | N/A | IPO Year: | 1944 |
| Target Price: | $172.23 | AVG Volume (30 days): | 6.9M |
| Analyst Decision: | Buy | Number of Analysts: | 13 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 15.06 | EPS Growth: | 205.48 |
| 52 Week Low/High: | $143.13 - $175.97 | Next Earning Date: | 07-17-2024 |
| Revenue: | $78,713,000,000 | Revenue Growth: | 5.01% |
| Revenue Growth (this year): | 4.88% | Revenue Growth (next year): | 2.86% |
Stock Insider Trading Activity of Johnson & Johnson (JNJ)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Broadhurst Vanessa | JNJ | EVP, Global Corp Affairs | Mar 13 '24 | Sell | $162.16 | 8,891 | $1,441,764.56 | 15,043 | SEC Form 4 |
Latest Johnson & Johnson News
JNJ Breaking Stock News: Dive into JNJ Ticker-Specific Updates for Smart Investing
Simply Wall St.
12 hours ago
Is Johnson & Johnson (NYSE:JNJ) A Risky Investment?
Yahoo Finance
a day ago
'Never going to be the same': How Nvidia is trying to revolutionize healthcare
Pharmaceutical Technology
a day ago
AC Immune wins FDA fast track for Alzheimer’s vaccine candidate
Pharmaceutical Technology
a day ago
Sandoz launches ustekinumab biosimilar in Europe
Zacks
a day ago
AbbVie (ABBV) Beats on Q2 Earnings & Sales, Ups '24 EPS View
Investopedia
a day ago
AstraZeneca Posts Earnings Beat, Lifts Guidance on Strong Sales
Benzinga
2 days ago
How To Earn $100 Per Month From Johnson & Johnson Stock
Exec Edge
2 days ago
Claimants Face 5pm ET Fri Deadline to Accept $8 Billion Settlement in J&J Suit, Ovarian Cancer Survivors Urge Others to Vote “Yes”
Compare JNJ vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "JNJ Johnson & Johnson - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.